Results are in. LLY FY revenue guidance is up $2 billion, to $42 billion. Revenue & Pipeline: -Q1'24 revenue increased 26% YOY due to weight loss drugs -The GLP-1 market set to grow to $105 billion by 2029, 19.2% CAGR -LLY's TTM revenue primarily due to a 16% increase in realized prices, and 12% increase in volume for weight loss drugs -LLY's pipeline is heavy on weight loss and obesity, with a strong front runner in Tirzepatide. Phase III studies saw a mean body weight reduction btw 18.1%-20.1%, and strong results for chronic weight management, sleep apnea and cardiovascular therapies Capacity: -No substantive changes for 2024. North Carolina site likely to come online 2025 -Kwikpen was approved for Mounjaro launch in the EU (opens capacity) -Amazon reported earnings today-Amazon Pharmacy is launching same-day delivery in NYC, LA; drug portfolio not specifically covered -GNC and The Vitamin Shoppe will make space for Ozempic and Wegovy in 2,300 stores Coverage: -No substantive changes, except that revenue increases for LLY are primarily due to increase in realized prices Novo Nordisk reports earnings on May 2, 2024. https://lnkd.in/e_DHbiip
Keegan Rose Research
Financial Services
New York, NY 55 followers
Equity and product research
About us
Research Philosophy Equity research in technology, media and telecom verticals through cutting-edge methods, bespoke data modules, and data privacy governance.
- Website
-
www.keeganrosecapital.com
External link for Keegan Rose Research
- Industry
- Financial Services
- Company size
- 1 employee
- Headquarters
- New York, NY
- Type
- Self-Owned
- Founded
- 2024
Locations
-
Primary
Get directions
New York, NY 10023-0353, US
Updates
-
Eli Lilly Q1 2024 earnings call starts soon. Press Release has gone out. Here's what we're looking for from Eli Lilly: -An update on the Alzheimer's Phase III trials -An update on supply chain delays, insurance coverage -What their plan is for employers who removed the "weight loss" rider from their contracts -More important, how supply chain & insurance coverage will or will not delay revenue The revenue guidance is up, but we don't know what that means for product, consumers, and profitability in 2024. https://lnkd.in/eGEYeRBK
Eli Lilly Equity Research Company Update — Keegan Rose Research
keeganrosecapital.com
-
Eli Lilly Product Research across (3) separate products has been published. 160 weeks of data across 35 variables, analyzed on a daily basis. Research found 47.6% effectiveness in CGRP inhibitors and that effectiveness increased to 200% with simple additivity of GLP-1 agonists. Eli Lilly reports Q2 2024 earnings on Apr 30, 2024 at 10A EDT. White Paper here: https://lnkd.in/edNghk6S
-
-
Eli Lilly Product Research across (3) separate products has been published. 160 weeks of data across 35 variables, analyzed on a daily basis. Research found 47.6% effectiveness in CGRP inhibitors and that effectiveness increased to 200% with simple additivity of GLP-1 agonists. Eli Lilly reports Q1 2024 earnings on Apr 30, 2024 at 10A EDT. Novo Nordisk reports Q1 2024 earnings on May 2, 2024 at 7:30 CET. White Paper here: https://lnkd.in/edNghk6S
Every day for the last 160 weeks, I have had a migraine. Migraines are a genetic disease, which unfortunately, affects many members of my family. We have tried everything. My favorite recommendation comes from naturopaths: "Have you tried meditating?" 1 in 6 Americans are affected by migraine, and meaningful research is sparse. As an analyst, I began collecting daily data across 35 separate variables: level of pain, ancillary symptoms such as stomach pain, nausea, natural remedies, diet, exercise, sleep, stress levels, meal times, caloric intake, water intake, blood pressure, barometric pressure - just to name a few. Early in my treatment, I had the good fortune to test Eli Lilly's CGRP inhibitor, Emgality. I tested (3) Eli Lilly products in total, then analyzed their effectiveness over time. The first product increased treatment effectiveness by 47.6% (i.e. reduced pain level, intensity). Eli Lilly's Q1 2024 earnings call is tomorrow (Tue Apr 30 at 10A EDT). Some analysts have scratched their heads wondering how a pharma company could break into the Magnificent 7, surpassing Tesla, and be well on its way to becoming the first pharma company with a $1 Trillion valuation. Eli Lilly and Novo Nordisk are both vying for the coveted spot as market leader in weight loss drugs. During my research, I also tested Eli Lilly's product, Mounjaro, primarily used for Type 2 diabetes, and off label, for weight loss. (Findings are below). Because there is such sparse, meaningful data on migraine patients and their treatment, I have made my research publicly available, along with the underlying data framework. If you, anyone in your family, your friends, your colleague, your neighbor, an acquaintance through networking, or a friend of a friend is affected by headaches or migraines, I want this research, its findings, the underlying data, and the data framework to be available to you. White Paper here: https://lnkd.in/e8XQEC84 #EliLilly #CGRP #GLP1 #Emgality #Mounjaro #LLY #MigraineResearch #NeurologyResearch
-
-
Excited to announce forthcoming equity research across Technology, Media and Telecom. https://lnkd.in/eXqBSF-Z
-